Summary & Overview
CPT 81112: HPA-15 (S682Y) Genetic Analysis
CPT code 81112 covers the technical laboratory analysis of the two common alleles of Human Platelet Antigen 15 (HPA–15/S682Y) using specimens such as blood or amniotic fluid. This targeted genetic test is clinically relevant for platelet alloimmunization assessment, transfusion compatibility evaluation, and prenatal diagnostic considerations, making it an important assay in hematology, transfusion medicine, and maternal-fetal medicine. Nationally, molecular platelet antigen testing can affect blood bank operations, prenatal care workflows, and genetic counseling referrals.
Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for HPA–15 testing, typical sites of service and workflow implications, common modifier usage and billing considerations where applicable, and an outline of payer coverage patterns when available. The publication also provides benchmarking and policy-relevant notes to aid coding accuracy and payer communications. Data not available in the input is noted where applicable.
Billing Code Overview
CPT code 81112 describes a molecular diagnostic laboratory test that analyzes the genes encoding the two common alleles of Human Platelet Antigen 15 (HPA–15), also called S682Y. The procedure involves a laboratory analyst performing the technical component of the genetic assay on an appropriate specimen, such as blood or amniotic fluid.
-
Service type: Genetic laboratory testing / molecular diagnostic analysis
-
Typical site of service: Clinical laboratory or hospital-based laboratory using blood draw or amniotic fluid specimen
Clinical & Coding Specifications
Clinical Context
A 32-year-old pregnant patient with a prior fetal/neonatal alloimmune thrombocytopenia (FNAIT) in a prior pregnancy requires targeted platelet antigen genotyping. The clinician orders 81112 to determine maternal and fetal Human Platelet Antigen 15 (HPA‑15 / S682Y) allele status using maternal blood and, when indicated, amniotic fluid or chorionic villus specimen. The clinical workflow: specimen collection (peripheral blood or amniotic fluid) -> specimen accessioning and chain-of-custody -> DNA extraction -> targeted genotyping assay for HPA‑15 alleles -> technical analysis and result reporting. Results are used by maternal‑fetal medicine, transfusion medicine, or hematology teams to assess alloimmunization risk, guide antenatal monitoring, and inform transfusion planning for mother or neonate.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | When billing only the professional (interpretation) portion if the laboratory separates technical and professional components. |
TC | Technical component | When billing only the technical component (laboratory testing) without professional interpretation. |